KL-50 (also known as RR-004 by its developer Pharminox Limited) is a drug candidate designed to treat glioblastoma. It functions by alkylating DNA yielding O6-(2-fluoroethyl)guanine which causes DNA interstrand crosslinks. Half of the cancers are unable to repair the DNA damage.
The KL-50 molecule was patented by Pharminox Limited in 2013, detailing its potential use in treating MMR-/MGMT- gliomas.
References